Sign in

Trial result ·

Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study looked at hidradenitis suppurativa, a long-term skin disease. The team first studied skin tunnels with many lab tests. They found that IL-17 and IL-36 signals work together in these tunnels. This led them to make HB0043, an antibody that blocks both signals. They then tested it in an early trial in people with severe disease. Tunnels were the main problem in these people.

What they found

In the lab, HB0043 worked better than some other antibodies. At week 16, lumps and abscesses had dropped compared with the start. All people reached a set level of response on a standard score. Many also reached a stricter level of response. Scans showed the tunnels getting smaller. No major safety concerns were seen in the short term. Blood tests showed lower signs of inflammation. They also showed the body's metabolic balance returning to normal.

What it means for patients

The authors talk about blocking IL-17A and IL-36R together. They say this may be a possible way to treat this disease. They think it could help hard-to-treat disease with tunnels. They also say the antibody may help the skin heal its structure. In their view, a drug that hits both pathways can work where single drugs fail.

Why it is not certain yet

This was an early trial to test the idea. The abstract does not say how many people took part. It does not mention a comparison group. Safety was only judged in the short term. Early trials like this need larger studies to confirm the results.

Source

Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.

PubMed · PMID 42869887

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Hidradenitis suppurativa publications